Like Causes?

Install the App

senate Bill S. 1764

CARERS Act of 2017

Bill Details

Official information provided by the Congressional Research Service. Learn more or make a suggestion.
The Congressional Research Service writes summaries for most legislation. These summaries are listed here. Causes will update some legislation with a revised summary, title or other key elements.

Suggest an update to this bill using our form.


CARERS Act of 2017

Official Title

A bill to extend the principle of federalism to State drug policy, provide access to medical marijuana, and enable research into the medicinal properties of marijuana.


Compassionate Access, Research Expansion, and Respect States Act of 2017 or the CARERS Act of 2017 This bill amends the Controlled Substances Act to provide that the Act's regulatory controls and administrative, civil, and criminal penalties do not apply to a person who produces, possesses, distributes, dispenses, administers, tests, recommends, or delivers medical marijuana in compliance with state law. The bill also: excludes "cannabidiol" (CBD) from the definition of "marijuana"; limits the concentration of delta-9-tetrahydrocannabinol (THC) in CBD to 0.3 percent on a dry weight basis; and deems marijuana grown or processed to make CBD, in accordance with state law, to comply with the THC concentration limit unless the Drug Enforcement Administration (DEA) determines state law to be unreasonable. The bill directs the Department of Health and Human Services (HHS) to terminate the Public Health Service's interdisciplinary review process that is used to evaluate applications for medical marijuana research. The DEA must license manufacturers and distributors of marijuana for medical research; HHS must register practitioners to conduct research; and the Department of Veterans Affairs (VA) must authorize VA health care providers to provide recommendations and opinions to veterans regarding participation in their states' marijuana programs.

bill Progress

  • Not enacted
    The President has not signed this bill
  • The house has not voted
  • The senate has not voted
      senate Committees
      Committee on the Judiciary
    IntroducedSeptember 5th, 2017
    Give drug monitoring to the states.
    Cannabis has medicinal properties, or potential for medicinal properties. It certainly shouldn't be considered Schedule I. I think the Schedules need to be redone, perhaps by pharmacists and according to accurate chemical properties more than politics. We need to be able to research cannabis and acquire data on it in order to proceed with what could be a potential godsend for many people, such as regarding pain treatment or depression treatment and so forth. But we'll never know the potential for medicinal applications if we are barred from even researching it.